GH Guardant Health
- 29.940
- -0.560-1.84%
- 30.310
- +0.370+1.24%
Guardant Health News
Even After Rising 7.4% This Past Week, Guardant Health (NASDAQ:GH) Shareholders Are Still Down 74% Over the Past Three Years
United States Liquid Biopsy Market Forecast to 2031: Company Profiles, Recent Developments and Major Deals - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "United States Liquid Biopsy Market (by Circulating Biomarker, Product, Application, Cancer Types, Non-Cancer Application, End User, Clinical Application, Sample Type), In
Guardant Health(GH.US) Director Sells US$2,787 in Common Stock
$Guardant Health(GH.US)$ Director Joyce Meghan V. sold 100 shares of common stock on Jun 4, 2024 at an average price of $27.87 for a total value of $2,787.Source: Announcement What is statement of cha
Express News | Guardant Health Shares Are Trading Higher After the Company Launched the New Guardant360 TissueNext Test. Additionally, Canaccord Genuity Maintained a Buy Rating While Raising Its Price Target to $38
Guardant Health Is Maintained at Buy by Canaccord Genuity
Guardant Health Is Maintained at Buy by Canaccord Genuity
Express News | Canaccord Genuity Maintains Buy on Guardant Health, Raises Price Target to $38
Guardant Health Introduces New Guardant360 TissueNext Test With Nearly 500 Biomarkers to Identify More Treatment Options for Patients With Advanced Cancer
Upgraded gene panel on tissue genomic profiling test covers 498 biomarkers, including guideline-recommended genes Operational improvements streamline workflow and shorten time to results Upgraded t
Guardant Health Initiated at Buy by Jefferies
Guardant Health Initiated at Buy by Jefferies
Express News | Jefferies Initiates Coverage On Guardant Health With Buy Rating, Announces Price Target of $32
Guardant Health and Washington University to Present Study at 2024 ASCO Meeting Highlighting Utility of CtDNA to Address Racial Inequities in the Use of Targeted Therapies and Enrollment in Clinical Trials
Data from study using Guardant360 blood test show Black patients with PIK3CA mutations in advanced breast cancer were less likely than White patients to be enrolled in clinical trials and receive targeted
Express News | Guardant Health Inc : Jefferies Initiates Coverage With Buy Rating; Price Target $32
Guardant Health Enhances Executive Severance and Vesting Provisions
Guardant Health Named to TIME100 Most Influential Companies
Guardant's Impact, Innovation, Ambition, and Success Contributed to the Recognition Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its inclusion in the fourth-annual TIME100
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc (NASDAQ:HOOD), Moderna Inc (NASDAQ:MRNA), Palantir Technologies Inc (NYSE
Guardant Health (GH) Recently Broke Out Above the 200-Day Moving Average
Analysts Offer Insights on Healthcare Companies: Cooper Co (COO), Vertex Pharmaceuticals (VRTX) and Guardant Health (GH)
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersCue Health (NASDAQ:HLTH) stock moved upwards by 32.4% to $0.12 during Monday's pre-market session. The market value of their outstanding shares is at $19.8 million. SCWorx (NASDAQ:WORX) shares
Evaluating Guardant Health: Insights From 5 Financial Analysts
In the preceding three months, 5 analysts have released ratings for Guardant Health (NASDAQ:GH), presenting a wide array of perspectives from bullish to bearish.In the table below, you'll find a summa
Research Alert: CFRA Maintains Buy Opinion On Shares Of Guardant Health, Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month target price by $3
Analysis
Price Target
No Data
